Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

Peer Review reports

Original Submission
12 Feb 2012	Submitted	Original manuscript
2 May 2012	Reviewed	Reviewer Report - Stuart James Peacock
5 May 2012	Reviewed	Reviewer Report - Yi-Long Wu
6 May 2012	Reviewed	Reviewer Report - Chun-Ru Chien
30 May 2012	Author responded	Author comments - christos chouaid
Resubmission - Version 2
30 May 2012	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
16 Jun 2012	Author responded	Author comments - christos chouaid
26 Jun 2012	Reviewed	Reviewer Report - Stuart James Peacock
Resubmission - Version 4
16 Jun 2012	Submitted	Manuscript version 4
Publishing
27 Jun 2012	Editorially accepted
20 Jul 2012	Article published	10.1186/1471-2407-12-301

Back to article page